id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-288311-8kcturbn	Fassihi, Safa C.	Novel Approach for Low‐Dose Pulmonary Delivery of Hydroxychloroquine in COVID‐19	2020-06-19		.txt	text/plain	1536	86	47	This lack of clinical efficacy in treating asthma cannot be translated to COVID-19, which has a different etiology for pulmonary inflammation and is a disease process that stands to benefit from the anti-viral effects of HCQ. Although further evidence is needed to determine the efficacy of aerosolized HCQ in the treatment of COVID-19, low-dose targeted pulmonary delivery represents a safe and potentially preferred delivery method, particularly given the purported mechanisms by which HCQ acts against SARS-CoV-2. In light of the consequences seen with widespread use of high-dose, orally-administered HCQ in the treatment of COVID-19, clinical testing of the pharmacological parameters of inhaled or nebulized HCQ should be a high priority. However, if HCQ is to be administered in critically ill COVID-19 patients, low-dose inhaled or nebulized therapy may confer the collective benefits of similar or greater drug concentrations in pulmonary tissues, less systemic adverse effects (including cardiotoxicity), decreased burden on the healthcare system, and diminished strain on the existing supply of hydroxychloroquine.	./cache/cord-288311-8kcturbn.txt	./txt/cord-288311-8kcturbn.txt